TCM
COCH icon

Tegean Capital Management’s Envoy Medical COCH Stock Holding History

Tegean Capital Management’s Portfolio COCH Stock Details COCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-70,000
Closed -$686K – 41
2022
Q2 		$686K Hold
70,000
– – 0.03% 13
2022
Q1 		$684K Buy
+70,000
New +$681K 0.72% 12

Other funds holding COCH

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Tegean Capital Management's COCH Position: Q3 2022 in Review

Tegean Capital Management sold out of Envoy Medical (COCH) in Q3 2022, closing a stake of 70,000 shares — an estimated $686K sold.

Tegean Capital Management first reported a position in COCH in Q1 2022 and held it in 2 quarters. The position peaked at $686K in Q2 2022. 94 funds tracked by Wall St. Rank hold COCH as of Q3 2022.

  • Tegean Capital Management reported no remaining Envoy Medical position as of Q3 2022 after selling out during the quarter.
  • Tegean Capital Management sold 70,000 Envoy Medical shares in Q3 2022, an estimated $686K.
  • Tegean Capital Management first reported a position in Envoy Medical in Q1 2022 and held it in 2 quarters.
  • Tegean Capital Management's Envoy Medical position peaked at $686K in Q2 2022.
  • 94 funds tracked by Wall St. Rank held Envoy Medical as of Q3 2022.

Based on Tegean Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.